Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RELA is a ~65 kDa transcription factor and a key component of the NF-κB complex, most commonly forming a heterodimer with p50. In the cytoplasm, it is sequestered by IκB inhibitors. Upon stimulation by pro-inflammatory signals (e.g., TNF-α, LPS), IκBα is phosphorylated and degraded, releasing RELA/p65 to translocate into the nucleus, where it regulates transcription of genes involved in immunity, inflammation, cell survival, proliferation, and apoptosis. Its activity is tightly regulated by numerous post-translational modifications, which fine-tune DNA binding, coactivator recruitment, and turnover. Constitutive or aberrant activation of RELA is implicated in many cancers by promoting tumor survival and resistance to apoptosis, and in autoimmune and inflammatory diseases by driving pathological gene expression.
Drugs targeting RELA/NF-κB generally act via: - Inhibition of nuclear translocation of the RELA/p65 complex - Blocking IκBα degradation - Direct inhibition of RELA DNA binding - Interfering with post-translational modifications that regulate activity (e.g., phosphorylation, acetylation)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RELA proto-oncogene, NF-κB subunit (RELA (commonly referred to as p65)).